D. E. Shaw & Co. Inc. Sells 47,789 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

D. E. Shaw & Co. Inc. trimmed its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 18.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 217,813 shares of the specialty pharmaceutical company's stock after selling 47,789 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.68% of Collegium Pharmaceutical worth $6,240,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of COLL. Invesco Ltd. boosted its holdings in shares of Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock worth $50,876,000 after purchasing an additional 289,335 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Collegium Pharmaceutical by 0.3% during the 4th quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock valued at $47,603,000 after buying an additional 5,480 shares during the period. Northern Trust Corp grew its holdings in shares of Collegium Pharmaceutical by 5.6% during the 4th quarter. Northern Trust Corp now owns 385,157 shares of the specialty pharmaceutical company's stock valued at $11,035,000 after acquiring an additional 20,490 shares in the last quarter. Royce & Associates LP grew its holdings in shares of Collegium Pharmaceutical by 11.0% during the 4th quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company's stock valued at $9,728,000 after acquiring an additional 33,674 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Collegium Pharmaceutical by 19.5% in the fourth quarter. AQR Capital Management LLC now owns 154,216 shares of the specialty pharmaceutical company's stock worth $4,418,000 after acquiring an additional 25,206 shares during the last quarter.

Analyst Upgrades and Downgrades

COLL has been the topic of several research reports. StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. Piper Sandler restated a "neutral" rating and issued a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $43.80.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock traded up $0.13 during trading hours on Tuesday, reaching $29.96. 424,409 shares of the company were exchanged, compared to its average volume of 428,831. Collegium Pharmaceutical, Inc. has a 12 month low of $23.23 and a 12 month high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock has a 50-day moving average of $28.13 and a 200 day moving average of $29.80. The firm has a market cap of $962.67 million, a price-to-earnings ratio of 12.91 and a beta of 0.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by ($0.01). The firm had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Collegium Pharmaceutical's quarterly revenue was up 22.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.45 earnings per share. As a group, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Activity

In other news, EVP Scott Dreyer sold 2,255 shares of the business's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the transaction, the executive vice president now owns 124,421 shares in the company, valued at approximately $3,732,630. The trade was a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total value of $58,470.00. Following the transaction, the chief financial officer now owns 177,195 shares in the company, valued at $5,315,850. This represents a 1.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 81,693 shares of company stock valued at $2,334,994. 2.51% of the stock is owned by insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.